<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00416845</url>
  </required_header>
  <id_info>
    <org_study_id>CFTY720D2105</org_study_id>
    <nct_id>NCT00416845</nct_id>
  </id_info>
  <brief_title>Effects of FTY720 on Heart and Lung Functions in Healthy Volunteers</brief_title>
  <official_title>A Randomized, Parallel Group, Double-blind, Placebo Controlled, 14 Days Multiple-dose Treatment to Assess the Pulmonary and Cardiac Pharmacodynamics of FTY720 (0.5 and 1.25 mg) in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study is designed to assess the effects of two doses of FTY720 on lung (pulmonary) and&#xD;
      cardiac (heart) functions in healthy volunteers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <primary_completion_date type="Actual">March 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effects of two doses of FTY720 on lung and cardiac (heart) functions in healthy volunteers.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment initiation effect on heart rhythm.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of dynamic effect on heart rate and rhythm.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment initiation effect and duration of this effect on cardiac output and stroke volume.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment initiation effect and the duration of this effect on pulmonary function with methacholine challenge.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic effect on absolute lymphocyte count.</measure>
  </secondary_outcome>
  <enrollment type="Actual">39</enrollment>
  <condition>Healthy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FTY720</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy, non-smoking,(ie. 6 months w/o the use of nicotine or nicotine containing&#xD;
             products), male or female subjects.&#xD;
&#xD;
          -  Female subjects must be either surgically sterilized (including bilateral tubal&#xD;
             ligation) at least 6 months or post-menopausal. Postmenopausal women must have no&#xD;
             regular menstrual bleeding for at least 1 year prior to inclusion and menopause will&#xD;
             be confirmed by a plasma FSH level of &gt;40 IU/L.&#xD;
&#xD;
          -  Male subjects agree to refrain from sperm donation from check-in until 30 days beyond&#xD;
             the conclusion of all study events.&#xD;
&#xD;
          -  Male subjects must agree to the use of condoms with spermicide with sexual intercourse&#xD;
             from 14 days prior to check-in until 30 days beyond the last dose of study drug.&#xD;
&#xD;
          -  Resting heart rate â‰¥ 50 beats per minute (bpm)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History or presence of any clinically significant events, which in the opinion of the&#xD;
             investigator, would jeopardize the safety of the subject or impact the validity of the&#xD;
             study results.&#xD;
&#xD;
          -  Subjects with systolic blood pressure &lt; 90 mmHg or diastolic blood pressure &lt; 50 mmHg&#xD;
&#xD;
          -  Male subjects with a QTcB &gt; 450 msec&#xD;
&#xD;
          -  Female subjects with a QTcB &gt; 470 msec&#xD;
&#xD;
          -  Subjects with pulmonary symptoms, history of exercise-induced asthma, asthma or&#xD;
             chronic obstructive pulmonary disease (COPD)&#xD;
&#xD;
          -  Use of any prescription drug within 1 month of starting the study&#xD;
&#xD;
          -  Positive urine screen for alcohol or drugs at screening, unless the test is shown to&#xD;
             be falsely positive on confirmation testing.&#xD;
&#xD;
          -  Hemoglobin &lt; 12g/dL&#xD;
&#xD;
          -  Donation of blood or significant blood loss within 56 days prior to check in.&#xD;
&#xD;
          -  Donation of plasma within 7 days prior check in.&#xD;
&#xD;
          -  Participation in an investigational study within 30 days prior to check in.&#xD;
&#xD;
          -  Positive screening test for HIV or Hepatitis B or C.&#xD;
&#xD;
          -  A past history of cigarette smoking of &gt; 10 pack-years or use of nicotine or&#xD;
             nicotine-containing products 6 months prior to dosing.&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis</last_name>
    <role>Principal Investigator</role>
    <affiliation>Investigator site</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>East Hanover</city>
        <state>New Jersey</state>
        <zip>07936-1080</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <study_first_submitted>December 27, 2006</study_first_submitted>
  <study_first_submitted_qc>December 27, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 28, 2006</study_first_posted>
  <last_update_submitted>June 3, 2010</last_update_submitted>
  <last_update_submitted_qc>June 3, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 4, 2010</last_update_posted>
  <keyword>pharmacodynamic effects, cardiac effects, healthy subjects, synthetic sphingosine 1 phosphate (S1P) receptor modulator</keyword>
  <keyword>Healthy male and female subjects</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fingolimod Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

